Patent: 8,846,681
✉ Email this page to a colleague
Summary for Patent: 8,846,681
| Title: | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
| Abstract: | The present invention provides compounds of Formula I, including tautomers, resolved enantiomers, diastereomers, solvates, metabolites, salts and pharmaceutically acceptable prodrugs thereof. ##STR00001## Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer. |
| Inventor(s): | Mitchell; Ian S. (Lafayette, CO), Blake; James F. (Longmont, CO), Xu; Rui (Longmont, CO), Kallan; Nicholas C. (Boulder, CO), Xiao; Dengming (Longmont, CO), Spencer; Keith Lee (Lyons, CO), Bencsik; Josef R. (Longmont, CO), Wallace; Eli M. (Lyons, CO), Schlachter; Stephen T. (Boulder, CO), Banka; Anna L. (Longmont, CO), Liang; Jun (Palo Alto, CA), Safina; Brian (Redwood City, CA), Li; Jun (Foster City, CA), Chabot; Christine (San Mateo, CA) |
| Assignee: | Array BioPharma, Inc. (Boulder, CO) Genentech, Inc. (South San Francisco, CA) |
| Application Number: | 13/160,351 |
| Patent Claims: | see list of patent claims |
Details for Patent 8,846,681
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | ⤷ Try a Trial | 2027-07-05 |
| Idec Pharmaceuticals Corp. | RITUXAN | rituximab | Injection | 103737 | 02/19/2002 | ⤷ Try a Trial | 2027-07-05 |
| Hoffmann-la Roche Inc. | ZENAPAX | daclizumab | Injection | 103749 | 12/10/1997 | ⤷ Try a Trial | 2027-07-05 |
| Swedish Orphan Biovitrum Ab (publ) | SYNAGIS | palivizumab | For Injection | 103770 | 06/19/1998 | ⤷ Try a Trial | 2027-07-05 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
